FY2029 EPS Forecast for TuHURA Biosciences Lifted by Analyst

Key Points

• Brookline Capital Markets raised FY2029 EPS — analyst K. Raja boosted TuHURA Biosciences' FY2029 EPS forecast to $0.11 (from $0.06) and also projects $0.52 EPS for FY2030.
• Recent results and analyst sentiment are mixed — the company reported a Q1 loss of ($0.13) versus ($0.12) expected, and analysts' ratings range from Buy to Sell with a consensus "Hold" and a $9.00 price target while shares trade near $2.27.

TuHURA Biosciences, Inc. (NASDAQ:HURA - Free Report) - Equities research analysts at Brookline Capital Markets upped their FY2029 earnings per share (EPS) estimates for shares of TuHURA Biosciences in a report issued on Thursday, April 9th. Brookline Capital Markets analyst K. Raja now forecasts that the company will earn $0.11 per share for the year, up from their prior forecast of $0.06. Brookline Capital Markets also issued estimates for TuHURA Biosciences' FY2030 earnings at $0.52 EPS.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01).

Several other equities analysts have also recently commented on the company. Weiss Ratings reiterated a "sell (e+)" rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. Wall Street Zen cut TuHURA Biosciences from a "hold" rating to a "sell" rating in a research note on Tuesday, April 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of TuHURA Biosciences in a research note on Tuesday, February 3rd. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $9.00.

TuHURA Biosciences Price Performance

NASDAQ HURA opened at $2.27 on Monday. The stock has a market cap of $144.33 million, a PE ratio of -3.60 and a beta of -0.32. TuHURA Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $4.44. The business has a 50 day moving average price of $1.51 and a two-hundred day moving average price of $1.59.

Hedge Funds Weigh In On TuHURA Biosciences

Several large investors have recently added to or reduced their stakes in HURA. Virtu Financial LLC bought a new position in TuHURA Biosciences during the third quarter worth $26,000. JPMorgan Chase & Co. bought a new position in TuHURA Biosciences during the second quarter worth $27,000. Wells Fargo & Company MN lifted its stake in TuHURA Biosciences by 109.0% during the fourth quarter. Wells Fargo & Company MN now owns 38,208 shares of the company's stock worth $29,000 after purchasing an additional 19,931 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in TuHURA Biosciences during the fourth quarter worth $30,000. Finally, Invesco Ltd. bought a new position in TuHURA Biosciences during the second quarter worth $30,000. 0.62% of the stock is currently owned by institutional investors.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company's core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA's approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.